J. Q. Tran

发表

Assessment of the Potential Pharmacokinetic and Pharmacodynamic Interactions between Erythromycin and Argatroban

D. Jorkasky, L. Benincosa, M. J. Hursting, 1999, Journal of clinical pharmacology.

Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis

J. Elkins, Alvydas Mikulskis, A. Othman, 2016, Clinical pharmacology : advances and applications.

Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS

S. Zamvil, B. Cree, H. Southworth, 2020, Neurology: Neuroimmunology & Neuroinflammation.

A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail

P. N. Morcos, Patrick F. Smith, Linda Chang, 2013, European Journal of Clinical Pharmacology.

Population PK-PD analyses of CD25 occupancy, CD56bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis.

I. Nestorov, A. Othman, Yaming Hang, 2016, British journal of clinical pharmacology.

Concentration‐QTc Modeling of Ozanimod’s Major Active Metabolites in Adult Healthy Subjects

Peijin Zhang, M. Palmisano, E. Briggs, 2020, CPT: pharmacometrics & systems pharmacology.

Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator

Peijin Zhang, R. Hargreaves, D. Dalvie, 2021, Drug Metabolism and Disposition.

Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials

J. Sheridan, A. Othman, M. Minocha, 2015, Clinical Pharmacokinetics.

Pharmacokinetic interaction between amprenavir and delavirdine: Evidence of induced clearance by amprenavir

M. Garrett, B. Hee, C. Petersen, 2002, Clinical pharmacology and therapeutics.

Effects of High‐ and Low‐Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator

J. Hartung, Cindy‐ann Tompkins, P. Frohna, 2017, Clinical pharmacology in drug development.

Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a–Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders

R. Petric, E. Gane, D. Larrey, 2013, Antimicrobial Agents and Chemotherapy.

Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects

Peijin Zhang, Atalanta Ghosh, M. Palmisano, 2020, Advances in Therapy.

Delavirdine: clinical pharmacokinetics and drug interactions.

J. Gerber, B. Kerr, J. Q. Tran, 2001, Clinical pharmacokinetics.

38 RITONAVIR BOOSTING OF LOW DOSE RG7227/ITMN-191, HCV NS3/4A PROTEASE INHIBITOR, RESULTS IN ROBUST REDUCTION IN HCV RNA AT LOWER EXPOSURES THAN PROVIDED BY UNBOOSTED REGIMENS

C. Stedman, A. Horban, E. Gane, 2010 .

Impact of Low-Dose Ritonavir on Danoprevir Pharmacokinetics

Yuan Chen, M. Reddy, Patrick F. Smith, 2012, Clinical Pharmacokinetics.

Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.

Ying Zhang, C. Stedman, A. Horban, 2011, Journal of hepatology.

Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible

Micaela B. Reddy, A. Connor, Philip Evans, 2011, Biopharmaceutics & drug disposition.

753 IMPACT OF LOW DOSE RITONAVIR BOOSTING ON THE PHARMACOKINETICS OF RG7227 (ITMN-191), A HIGHLY POTENT AND SELECTIVE INHIBITOR OF THE HCV NS3/4A PROTEASE

Patrick F. Smith, J. Haznedar, S. Blotner, 2010 .

Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator

R. Peach, H. Rosen, M. Boehm, 2017, Journal of clinical pharmacology.

Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I–III Clinical Trials

I. Nestorov, A. Othman, Yaming Hang, 2016, Clinical Pharmacokinetics.

Remyelination therapy goes to trial for multiple sclerosis

Mike P. Wattjes, Frederik Barkhof, Soma Ray, 2014, Neurology: Neuroimmunology & Neuroinflammation.

In Vitro Antiviral Activity and Single-Dose Pharmacokinetics in Humans of a Novel, Orally Bioavailable Inhibitor of Human Rhinovirus 3C Protease

F. Maldonado, S. Binford, M. A. Brothers, 2005, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers: Integrated Analysis of Intravenous and Subcutaneous, Single- and Multiple-Dose Administration

S. Dutta, A. Othman, M. Tang, 2014, Clinical Pharmacokinetics.

Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.

J. Elkins, A. Othman, J. Q. Tran, 2016, British journal of clinical pharmacology.

Morning Spot and 24‐Hour Urinary 6β‐Hydroxycortisol to Cortisol Ratios: Intraindividual Variability and Correlation under Basal Conditions and Conditions of CYP 3A4 Induction

S. J. Kovacs, J. Q. Tran, D. Martin, 1999, Journal of clinical pharmacology.

Cardiac Safety of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study

R. Peach, M. Boehm, A. Olson, 2017, Clinical pharmacology in drug development.

Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study

Peijin Zhang, Atalanta Ghosh, M. Palmisano, 2020, Advances in Therapy.

62 ACTIVITY OF DANOPREVIR PLUS LOW-DOSE RITONAVIR (DNV/R) IN COMBINATION WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN (PEGIFNa-2A/RBV) IN PREVIOUS NULL RESPONDERS

B. Gujral, E. Gane, D. Larrey, 2011 .

A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail

P. N. Morcos, Patrick F. Smith, Linda Chang, 2013, European Journal of Clinical Pharmacology.

1180 RITONAVIR SUBSTANTIALLY REDUCES REACTIVE METABOLITE FORMATION OF THE HCV PROTEASE INHIBITOR DANOPREVIR BOTH IN VITRO AND IN VIVO

T. Singer, P. Goelzer, P. N. Morcos, 2012 .

Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.

J. Elkins, A. Othman, J. Q. Tran, 2016, British journal of clinical pharmacology.

Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible

A. Connor, Philip Evans, M. Reddy, 2011, Biopharmaceutics & drug disposition.

Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis

J. Elkins, Alvydas Mikulskis, J. Q. Tran, 2016 .

Clinical Pharmacology: Advances and Applications Dovepress Pharmacokinetics of Daclizumab High-yield Process with Repeated Administration of the Clinical Subcutaneous Regimen in Patients with Relapsing- Remitting Multiple Sclerosis

J. Elkins, Alvydas Mikulskis, A. Othman, 2022 .